Robust data integration method for classification of biomedical data
Present a protocol to integrate two types of biological data –
clinical and molecular – for more effective classification of cancer patients. The proposed approach is a hybrid between early and late data integration strategy. In this hybrid protocol, the set of informative clinical features is enhanced by classification results based on molecular data sets. The results are then treated as new synthetic variables. The hybrid protocol was applied to METABRIC breast cancer specimens and TCGA urothelial bladder carcinoma specimens. Various data types were used for clinical endpoint prediction: clinical data, gene expression, somatic copy number aberrations, RNA-Seq, methylation and reverse phase protein array.
The performance of hybrid data integration was assessed with repeated cross validation process and compared to other methods of data integration: early integration and late integration via super learning. The hybrid method gave similar results to those obtained by the best tested variants of SuperLearning. What’s more, the hybrid method allowed for further sensitivity analysis and recursive feature elimination, leading to compact predictive models for cancer clinical endpoints.
For breast cancer, the final model includes eight clinical variables and two synthetic features derived from molecular data. For urothelial bladder carcinoma, only two clinical features and one synthetic variable were necessary to produce the best predictive model. We have shown that the inclusion of synthetic variables based on RNA expression levels and copy number changes can improve the quality of prognostic tests. Thus, it should be considered for inclusion in wider medical practice.
A bacteria-induced morphology genetic biomedical material: self-propelled artificial microbots for metastatic triple negative breast cancer treatment.
Morphology Genetic Biomedical Materials (MGBMs), referring to the creation of materials by learning from genetic morphology and natural species strategies, have great potential for biomedical applications. Inspired by cargo-carrying-bacterial therapy (microbots) to treat cancer, a mGBM (artificial microbots, AMB) was constructed. Rather than having inherent bacterial properties (cancer chemotaxis, tumor invasion, cytotoxicity), AMB also possessed simple nitric oxide (NO) generation strategy.
Mimicking the bacterial construct, hyaluronic acid (HA) polysaccharide was induced as a coating capsule of AMb to achieve prolonged circulation and specific tissue preference (tumor tropism) in the blood. Covered under capsule-like polysaccharides, combinatorial agents produced by amphiphilic dendrons self-assembly with abundant L-arginine residues peripherally (as endogenous NO donor) and hydrophobic chemotherapeutic drugs core stacking on the surface of SWNTs On (photothermal agent) for a strong chemo-photothermal therapy (chemo-PTT) and immunotherapy achieved.
Subsequently, the classic inducible nitric oxide synthase (iNOS) pathway resulting from the immune response was used to radically oxidize L-arginine substrates for NO production, for which the process was characterized by high reactive oxygen generated by chemo-PTT. Can also be promoted by species level. , NO generated by AmB was intended to regulate vasodilation and induce a dramatic invasion (in the form of microbots) to propel therapeutic agents into solid tumors for a more advanced therapeutic effect, which we refer to as “self-propulsion”. was defined. Self-propelled AMBs offer pioneering potential therapeutic opportunities, and offer broad potential in biomedical application, while demonstrating distant metastasis regression for the eradication of dominant primary tumors as well as to conquer metastatic triple negative breast cancer.
NATtrol Flu/RSV/SARS-CoV-2 Negative Control (6 x 0.5mL) |
|||
| NATCV9-6C | Zeptometrix | 6 x 0.5mL | 220 EUR |
NATtrol Flu/RSV/SARS-CoV-2 Positive Control (6 x 0.5mL) |
|||
| NATFRC-6C | Zeptometrix | 6 x 0.5mL | 240 EUR |
NATtrol Flu/RSV/SARS-CoV-2 External Run Control (6 x 0.5mL) |
|||
| NATFRC-ERC | Zeptometrix | - | 278 EUR |
NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Stock |
|||
| NATSARS(COV2)-ST | Zeptometrix | Stock | 935 EUR |
NATtrol SARS-CoV-2 Variant Panel (4 x 0.5mL) |
|||
| NATSARS(COV2)-VP | Zeptometrix | 4 x 0.5mL | 373 EUR |
NATtrol SARS-CoV-2 (recombinant) Stock (1 x 1.0mL) |
|||
| 0831042 | Zeptometrix | - | 693 EUR |
NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Stock (1mL) |
|||
| NATSARS(COV2-SA)-ST | Zeptometrix | 1 mL | 980 EUR |
NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.1.7 Stock (1mL) |
|||
| NATSARS(COV2-UK)-ST | Zeptometrix | 1 mL | 980 EUR |
NATtrol SARS-CoV-2 (E/ORF1ab recombinant) Stock (1 x 1.0mL) |
|||
| 0831043 | Zeptometrix | - | 693 EUR |
NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Negative Control (6 x 0.5 mL) |
|||
| NATSARS(COV2)-NEG | Zeptometrix | 6 x 0.5 mL | 189 EUR |
NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Negative Control (6 x 1.0 mL) |
|||
| NATSARS(COV2)-NEG1 | Zeptometrix | 6 x 1.0 mL | 227 EUR |
NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) External Run Control (6 x 0.5 mL) |
|||
| NATSARS(COV2)-ERC | Zeptometrix | 6 x 0.5 mL | 416 EUR |
NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) External Run Control (6 x 1.0 mL) |
|||
| NATSARS(COV2)-ERC1 | Zeptometrix | 6 x 1.0 mL | 568 EUR |
NATtrol RSV Positive Control (6 x 0.5mL) |
|||
| NATRSV-6C | Zeptometrix | 6 x 0.5mL | 222 EUR |
NATtrol Coronavirus SARS Stock (Qualitative) (1 mL) |
|||
| NATSARS-ST | Zeptometrix | 1 mL | 638 EUR |
NATtrol RSV Positive Control (6 X 0.5 mL) |
|||
| MDZ047 | Zeptometrix | 6 X 0.5 mL | 278.4 EUR |
NATtrol RSV Positive Control (6 X 0.5 mL) |
|||
| NATRSV-6C-IVD | Zeptometrix | 6 X 0.5 mL | 242 EUR |
NATtrol Flu Verification Panel (7 X 0.5 mL) |
|||
| NATFVP-NNS | Zeptometrix | 7 X 0.5 mL | 417 EUR |
SARS-CoV-2 (COVID-19) Antigen Rapid Test Kit (Colloidal Gold)
The Green Spring® SARS-CoV-2 Antigen Rapid Test Kit is used for the detection of SARS-CoV-2 antigen by the method of colloidal gold immunochromatographic assay. The mouse antibody α to 2019nCoV is labeled by colloidal gold, the test line (T) is coated with the mouse antibody β of 2019nCoV and the control line is coated with goat anti-mouse antibody. When SARS-CoV-2 antigen is introduced into the sample, the antigen binds with antibody α labeled with colloidal gold and conjugates to the immune-complex. Fluid complexes are captured by a line of mouse antibody β to 2019nCoV as they migrate to the test line (T). A lot of colloidal gold collects and a red line/belt appears. The remaining complexes move across the control line (C) and conjugate with goat anti-mouse antibodies, collecting a lot of colloidal gold and a red line/belt appears. When the sample does not contain the SARS-CoV-2 antigen, only a red line/belt formed by the mouse antibody α to 2019nCoV labeled by colloidal gold at the control (C) position is visible.
